FDA says Xarelto reduced fatal heart attacks

WASHINGTON (AP) - The Food and Drug Administration says a blood
thinner from Johnson & Johnson appears to reduce life-threatening
blood clots in high-risk patients, although it also increases the
risk of internal bleeding.
The FDA posted its review of J&J's Xarelto for the new use ahead
of a public meeting Wednesday where medical experts will assess its
safety and effectiveness.
J&J already markets Xarelto for two indications: irregular
heartbeat and for patients undergoing hip or knee replacement
surgery.
J&J is now asking the FDA to approve it as a treatment for
life-threatening blood clots in patients with narrowed blood
vessels, who are at increased risk for heart attack, stroke and
other catastrophic problems.
FDA reviewers say Xarelto appears to reduce those problems,
though J&J's study was missing several key data points.


Comments are posted from viewers like you and do not always reflect the views of this station.
powered by Disqus
WYMT CONTACT INFO 199 Black Gold Blvd. Hazard, KY 41701 606-436-5757 - switchboard 606-439-9968 - newsroom
Copyright © 2002-2014 - Designed by Gray Digital Media - Powered by Clickability 152284685 - wkyt.com/a?a=152284685
Gray Television, Inc.